Cocrystal Pharma, Inc.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

COCP$1.03-6.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

	December 31,
2024 · 2023
Cash flows from operating activities:
Net loss	$(17,504)		$(17,984)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	126		189
Right of use assets	320		(1,577)
Stock-based compensation	643		801
Change in operating lease liabilities	(210)		1,563
Changes in operating assets and liabilities:
Tax credit receivable	(325)		(174)
Prepaid expenses and other current assets	1,343		470
Deposits	17		-
Accounts payable and accrued expenses	(895)		2,046
Net cash used in operating activities	(16,485)		(14,666)
Investing activities:
Purchases of property and equipment	(8)		(118)
Net cash used in investing activities	(8)		(118)
Financing activities:
Payments of finance lease obligations	-		(7)
Proceeds from sale of common stock, net of transaction costs	-		4,000
Net cash provided by (used in) financing activities	-		3,993
Net decrease in cash and restricted cash	(16,493)		(10,791)
Cash and restricted cash at beginning of period	26,428		37,219
Cash and restricted cash at end of period	$9,935		$26,428
Supplemental disclosure:
Non-cash investing and financing activities
Initial recognition of right-of-use assets and lease liabilities	$163	$	-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.